Organization (Hospital)
Cook Children's Health Care System
ClinicalTrials.gov lists Cook Children's Health Care System as lead sponsor of 11 trials. It has 8 active development programs and 5 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 2 registered with a 2026 start date. The dashed outline is the pace from the 2 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 1.4 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers Cook Children's Health Care System: 11 lead-sponsored trials and 1 legal-entity registration.
Disease areas (31)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Epilepsy | 3 |
| Brain Neoplasms | 2 |
| Cerebral Palsy | 2 |
| Cystic Fibrosis | 2 |
| Diffuse Intrinsic Pontine Glioma | 2 |
Showing 5 of 31 disease areas.
Trials by start year as sponsor or collaborator (8)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 2 |
| 2025 | 2 |
| 2024 | 1 |
| 2022 | 2 |
| 2021 | 2 |
| 2015 | 1 |
| 2013 | 1 |
| 2008 | 1 |
Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (8)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Trametinib | Lung Diseases, Interstitial | Phase 2 | 1 |
| Trametinib | Histiocytosis, Langerhans-Cell | Phase 2 | 1 |
| 18F-DOPA | Insulinoma | Phase 1 | 1 |
| 18F-DOPA | Adenoma, Islet Cell | Phase 1 | 1 |
| 18F-DOPA | Congenital Hyperinsulinism | Phase 1 | 1 |
Showing 5 of 8 active programs.
Approved assets (5)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Trametinib | 1 |
| Ipratropium | 1 |
| 18F-DOPA | 1 |
| OMEGAVEN | 1 |
| Stiripentol | 1 |
Journals published in (130)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| The Journal of pediatrics | 11 |
| Developmental medicine and child neurology | 6 |
| Pediatrics | 6 |
| Blood | 5 |
| Journal of pediatric surgery | 5 |
Showing 5 of 130 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 1 | 1 | 2023-10-10 |
Financing and grant events (6)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2024-11-26 | NIH grant | 414,233 | Reporter |
| 2024-03-21 | NIH grant | 418,311 | Reporter |
| 2024-02-08 | NIH grant | 454,820 | Reporter |
| 2023-04-19 | NIH grant | 455,691 | Reporter |
| 2022-03-14 | NIH grant | 473,553 | Reporter |
Showing 5 of 6 events.
Organization relationships (64)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| The University of Texas System | Co sponsors trial with | 5 |
| Harris Health System | Co sponsors trial with | 4 |
| Stanford University | Co sponsors trial with | 3 |
| University of California System | Co sponsors trial with | 3 |
| University of Washington | Co sponsors trial with | 3 |
Showing 5 of 64 relationships.
Latest dated events (33)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-06-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-05-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-09-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-03 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-01-08 | FDA inspection | FDA enforcement (warning and untitled letters, recalls, inspections, import refusals, debarment) |
Showing 5 of 33 events.
Biomarker capability evidence (12)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ABCC8 | Trial sponsor | Named in trial inclusion criteria |
| ALB | Trial collaborator | Named in trial inclusion criteria |
| KCNJ11 | Trial sponsor | Named in trial inclusion criteria |
| SCN1A | Trial sponsor | Named in trial inclusion criteria |
| SCN1A | Trial sponsor | Named in trial inclusion criteria |
Showing 5 of 12 evidence rows.
Biomarkers this organization publishes on (202)
Shown in this order: most publications first.
Showing 5 of 202 biomarkers.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, sponsor delivery record, sec-reported annual financials, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, and clia clinical laboratory certificates.